Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina
-
Published:2023-12-30
Issue:2
Volume:45
Page:379-389
-
ISSN:1590-1874
-
Container-title:Neurological Sciences
-
language:en
-
Short-container-title:Neurol Sci
Author:
Carnero Contentti EdgarORCID, López Pablo A., Pappolla Agustín, Alonso Ricardo, Silva Berenice, Deri Norma, Balbuena María E., Burgos Marcos, Luetic Geraldine, Alvez Pinheiro Amelia, Cabrera Mariela, Hryb Javier, Nofal Pedro, Pestchanker Claudia, Vrech Carlos, Tavolini Darío, Tkachuk Verónica, Zanga Gisela, Marrodan Mariano, Ysrraelit María Célica, Correale Jorge, Carrá Adriana, Federico Belén, Garcea Orlando, Fernandez Liguori Nora, Patrucco Liliana, Cristiano Edgardo, Giunta Diego, Alonso Serena Marina, Rojas Juan I.,
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine
Reference18 articles.
1. Sala de Situación Nacional COVID-19 -Nuevo Coronavirus 2019 SE 22 Año 2021. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.argentina.gob.ar/sites/default/files/2021/06/sala-04-6_se22.pdf 2. Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 27(6):864–870 3. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:17562864211012836 4. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, Group MSS (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175–187 5. Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC (2022) COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 29(1):82
|
|